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Background: IMD-0354 is a kind of hydrophobic small molecule inhibitor of IKKβ, which
can effectively inhibit the NF-κB pathway. Besides, IMD-0354 can inhibit a variety of tumor
cells in culture, but its poor water solubility and low utilization have limited its clinical
application.
Methods: In this study, IMD-0354 was synthesized through esterifying the folate acid (FA)
conjugated dextran (Dex) as well as the lauryl alcohol (LA).
Results:The particle (IMD/FA-Dex-LA) size was 212.13±10.62nm, the encapsulation effi-
ciency was 89.27±6.51%, and the drug loading was 4.25±0.42%. Cell viability studies
indicated that the IMD/FA-Dex-LA effectively inhibited survival of B16F10 cells in culture.
Meanwhile, Western Blotting results showed that the nuclear transport of NF-κB was
reduced after blocking the IKK pathway, which would thereby suppress melanoma cell
division and proliferation. Moreover, subcutaneous tumor implantation experiment revealed
that, the drug-loading complex had an obvious effect on suppressing melanoma cells.
Findings of this study demonstrated that the IMD-0354 loaded FA-Dex-LA was more
effective than IMD-0354 alone.
Conclusion: In summary, FA-Dex-LA has been successfully synthesized in this study,
which can serve as a carrier for hydrophobic drug. Further, it is believed the FA-Dex-LA
can potentially applied in cancer treatment.
Keywords: dextran, lauryl alcohol, folate acid, IKK inhibitor, melanoma
Introduction
It is well established that malignant melanoma (MM) is initiated by mutations in
epidermal melanocytes that cause de-regulation of the cell cycle. MM accounts for
65% of skin cancer mortalities and is one of the deadliest of all solid tumors.1–4
Currently, molecular targeted therapy is another option for cancer treatment, but it is
distinct from the mechanism of traditional antitumor drug therapy, in that it can block
cancer cell division and suppress its replication, thus restraining its killing effect.5,6
Studies have shown that, in melanoma and other cancer cells, activation of transcription
factor NF-κΒ can initiate mitotic and anti-apoptotic pathways. Therefore, there have been
many attempts to design inhibitors that can block these pathways.7,8 For example, the IKK
complex inhibitor IMD-0345 has been shown to suppress cancer cell growth and promote
apoptosis in culture. The drug selectivity is increased, but there are still challenges to
clinical application. For instance, addition of an organic solvent short half-life.9,10 To this
end, polymer nanomaterials are being developed with biocompatibility and release. As
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drug carriers, dextran microspheres have the advantage of
reducing drug side-effects, reducing drug tolerance, but have
poor stability.11,12 To solve these problems there is a need to
modify the surface of the dextran role in many physiological
processes methylation.
In this study, the natural polysaccharide polymer dex-
tran served as the hydrophilic shell, while the lauryl alco-
hol was used as the hydrophobic nuclear layer, so as to
synthesize the amphipathic molecule that could form the
micell drug carrier in water solution through self-
assembly. Subsequently, FA was introduced onto the dex-
tran surface to improve the targeting ability of the IMD/
Dex-LA nanoparticles. Moreover, the hydrophobic mole-
cular inhibitor IMD-0354 was also utilized to bind with
the micell material, and the complex was then employed
for drug loading by virtue of the hydrophobicity in the
micell core layer, thus improving the drug insolubility.
Later, drug release was assessed in phosphate buffer solu-
tion (PBS) to explore the function of the micell carrier.
Finally, the biocompatibility of the micell carrier was
evaluated, and the influence of IMD-0354 drug on the
melanoma cell survival rate was also assessed.
Materials and methods
Materials
Dex, LA, DMSO, BSA, MTT, and FAwere purchased from
Sigma (St. Louis, MO, USA). NF-κB and p65 were provided
by Lifecore Biomedical (Chaska, MN, USA). Murine
B16F10 and L929 cells were obtained from the Shanghai
Institute of Biochemistry and Cell Biology (Shanghai,
China). Balb/c male mice were purchased from Cyagen
Biosciences (Guangzhou) Inc. All animals were performed
in conformity to the Animal Welfare Act, and experiments
with them were approved by the Institutional Animal Care
and Treatment Committee of Central South University.
Preparation of drug microsphere without
IMD-0354
Synthesis of FA-Dex
In brief, 0.4 g FA was dissolved into 4 mL mixed solvent,
2 g N,N’-二N,N’-Dicyclohexylcarbodiimide (DCC) was
dissolved into 1 mL mixed solvent, 2 g Dex was dissolved
into 3 mL mixed solvent, and 2 g dimethyl amine pyridine
was dissolved into 10 mL mixed solvent; afterwards, the
mixed solvents containing different drugs were mixed to
react for 20 hours at room temperature in the dark. Then,
the reaction product was filtered, the filtrate was collected
in acetone, and the bright yellow precipitate was formed,
filtered, and precipitated; then, the dry FA-raw Dex was
collected and purified using the dextran gel column, and
the first part of the eluent was collected, followed by
freeze drying and testing of FA-Dex.
Synthesis of FA-Dex-LA
Briefly, 0.25 g FA-Dex was dissolved into 5 mL anhydrous
DMSO. Then, the reaction catalysts DCC and DMAP were
added at the molar ratio of LA:DCC:DMAP=1:3:0.3,
under nitrogen protection at the constant temperature of
60°C, and the mixture was continuously stirred for 48
hours using a magnetic stirrer. After reaction, the product
was transferred into the dialysis bag (MWCO=1 kDa) to
remove DMSO at 24 hours following dialysis with deio-
nized water. After dialysis for 24 hours, the product was
placed into the separation funnel, and an equivalent
volume of ethyl acetate was added for extraction and
purification. After purification, the ethyl acetate was com-
pletely removed through 24 hours of dialysis with deio-
nized water (MWCO=1 kDa); finally, the powder obtained
by freeze-drying was FA-Dex-LA.
Preparation of microspheres loaded with
IMD-0354 drug
FA-Dex-LA and IMD-0354 were dissolved into 1 mL DMSO
at a mass ratio of 20:1 under room temperature, followed by
30 minutes of stirring using a magnetic stirrer. Afterwards,
1 mL deionized water was added to stir for 3 hours, so as to
crosslink the drug in hydrophobic nuclei to form the drug-
loaded microsphere solution. Following reaction, deionized
water was added for 24 hours of dialysis to completely
remove the residual drug and DMSO out of the hydrophobic
nuclei. After 24 hours of dialysis, the large-size matters and
microsphere clusters in the drug-loaded microsphere solution
were filtered with the 0.45 μm sieve, and then the solution
was preserved in a refrigerator at −80°C. The drug-loaded
microsphere was obtained by freeze-drying, named IMD/FA-
Dex-LA, and preserved in a refrigerator at −20°C.
Characterization of the nano drug carrier
The prepared FA-Dex-LA and IMD/FA-Dex-LA were ana-
lyzed by infrared (IR) spectroscopy, detection of micro-
sphere diameters, as well as other characterization methods.
Biocompatibility
Lyophilized microspheres (0.01–1 mg/mL) were dissolved
in the culture medium to co-culture for 24 hours. Each
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concentration was repeated for six times. After 24 hours of
culture, the microsphere-containing culture medium was
extracted and washed with 100 μL PBS twice. Afterwards,
20 μL MTT and 80 μL fresh culture medium were added
into the carbon dioxide incubator to react for 4 hours in the
dark; the resulting purple crystals were then dissolved and
sufficiently mixed with 200 μL DMSO, and the wave-
length was measured at 570 nm using ELISA.
Evaluation of the effects of IMD/FA-Dex-
LA microspheres and pure IMD-0354 on
inhibiting cell survival
Lyophilized IMD/FA-Dex-LA microspheres and pure
IMD-0354 were dissolved into the culture medium (at
the drug concentration of 0.1–10 μg/mL) for co-culture.
Then, the drug-containing culture medium was extracted
for MTT assay at 48 hours, respectively, and cell viability
was calculated.
Detection of pinocytosis
The microspheres were labeled with fluorescence sub-
stance FITC (Ex/Em=492 nm/518 nm), so as to observe
the pinocytosis of FA-Dex-LA by microspheres.
Western blotting
Cells were cultured with pure FA-Dex-LA micro-
spheres as well as the culture medium containing
IMD-0354 and IMD/FA-Dex-LA (at the drug concen-
tration of 0.5 μg/mL) for 24 hours. Subsequently, the
total cell protein was collected, and the expression of
IKK, IκB, NF-κB, pIKK, and pIκB was detected.
Animal studies
In this experiment, the 4–5-week-old Balb/c male mice
weighing 20–22 g were purchased from Cyagen
Biosciences Inc. (Guangzhou, China). Before seeding in
animals, B16F10 was washed with PBS and diluted to 105
cells/μL, then 10 μL of the resulting solution was aspirated
using a 30 G insulin syringe and seeded in the back of
each mouse. After tumor cell seeding, the tumor volume
was measured, photographed, and recorded once every 3
days. For all tumor volumes and sizes in the experiment,
the long axis (a), short axis (b), and thickness (c) were
measured using an electronic light-value scale, and were
calculated according to the following formula: tumor
volume (mm3)=0.5×a (mm)×b (mm)×c (mm).
1. Control Group: No treatment was received, and the
volumes were measured, photographed and recorded
once every 3 days.
2. FA-Dex-LA Group: Treatment was initiated when
the tumor grew to ~50 mm3 on Day 10;40 mg/kg
FA-Dex-LA was injected via the caudal vein
using a 29G syringe once every 7 days for three
cycles.
3. IMD0354 Group: Treatment was initiated when
the tumor grew to ~50 mm3 on Day 10;40 mg/kg
IMD0354 was injected via the caudal vein using
a 29G syringe once every 7 days for three
cycles.
4. IMD0354/FA-Dex-LA Group: Treatment was
initiated when the tumor grew to ~50 mm3 on Day
10;40 mg/kg Curcumin Micelles was injected via
the caudal vein using a 29G syringe once every 7
days for three cycles.
All animal experiments were conducted under the
appropriate approval of the Institutional Animal Care and
Treatment Committee of Central South University.
Statistical analysis
All data were expressed as mean±standard deviation (SD).
The means was compared between two samples using stu-
dent’s t-test. A difference of p<0.05 was deemed statistically
significant.
Results
Structural identification of the FA-Dex-
LA microspheres
Structural characteristic peak signals of FA-Dextran are
shown in Figure 1A, wherein the signals are detected at
ν=1,697−1 cm. Figure 1B displays the characteristic peak
signals of Lauryl alcohol. As pointed out by the refer-
ences, the absorption characteristic peak was observed at
ν=1,643 cm−1. It can be seen from Figure 1C that the C=O
stretching vibration absorption in ester group of FA-Dex-
LA was weak, at 1,736 cm−1 in the experiment, which
could be ascribed to the low FA graft degree. Moreover,
the FTIR spectra further confirmed the formation of the
FA-Dex-LA conjugate.
Microsphere particle size analysis
The particle size detection results of the pure FA-Dex-
LA microsphere and the FA-Dex-LA loaded with drugs
Dovepress Liu et al
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are presented in Table 1. As could be observed, the
average particle size of FA-Dex-LA was 154.35±8.76
nm, while that of the IMD/FA-Dex-LA was 212.13
±10.62 nm.
Drug encapsulation rate and loading
rate of the microsphere loaded with
IMD-0354
Table 2 displays the encapsulation rate and drug load-
ing rate of the drug loading IMD/FA-Dex-LA micro-
sphere. The materials-to-medicines ratio was 20:1
(w:w), the encapsulation rate of FA-Dex-LA was
89.27±6.51%, and the drug loading rate was
4.25±0.42%.
Drug release of the IMD-0354 loaded
microsphere
Figure 2 shows the drug release curve of the IMD0354/
FA-Dex-LA microsphere. As could be observed, the accu-
mulated drug release rate reached 52.7±9.4% within the
first 12 hours, 71.8±10.3% within the first 48 hours, and
83.9±7.2% within the first 72 hours, respectively.
Biocompatibility assessment of the
FA-Dex-LA microsphere
Biocompatibility of the material was assessed according to the
cytotoxicity test method for ISO10993-5 material. The test
Figure 1 FTIR diagram of FA-Dextran (A), Lauryl alcohol (B), and FA-Dex-LA (C).
Abbreviations: Dex, dextran; FA, folate acid; FTIR, Fourier-transform infrared spectroscopy; LA, lauryl alcohol.
Table 1 Average particle size of FA-Dex-LA and IMD/FA-Dex-LA
Type Size (nm) PDI
FA-Dex-LA 154.35±8.76 0.54±0.18
IMD/FA-Dex-LA 212.13±10.62 0.65±0.36
Abbreviations: Dex, dextran; FA, folate acid; LA, lauryl alcohol.
Table 2 Encapsulation rate and drug loading rate of FA-Dex-LA
microsphere
FA-Dex-LA:
IMD (w/w)
EE (%) DE (%)
IMD/FA-Dex-LA 20:1 89.27±6.51 4.25±0.42
Abbreviations: Dex, Dextran; FA, Folate Acid; LA, Lauryl Alcohol; PDI, Polymer
Dispersity Index; EE, Encapsulation Efficiency; DE, Drug-loading Efficiency.
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Figure 2 Drug release curve of IMD/FA-Dex-LA microsphere.
Abbreviations: Dex, dextran; FA, folate acid; LA, lauryl alcohol.
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results are shown in Figure 3. As could be seen, the survival
rates were 92.4, 95.5, 93.3, 95.2 and 83.3%, respectively, at the
material concentrations from low to high (Figure 3A).
Evaluation of the effects of IMD0354/
FA-Dex-LA microsphere and IMD-0354
drug alone on cancer cell survival rate
As shown in Figure 3B, no significant difference was
observed in cell inhibition rate between the two groups
at low concentrations. However, the difference in the cell
inhibition rate was markedly increased between the two
groups as the drug concentration increased (p<0.05).
Moreover, the inhibition rate of the carrier group was
remarkably higher than that of the single drug alone group.
Cellular pinocytosis of the FITC-FA-Dex-
LA microsphere
Figure 4 shows the results of the FITC-FA-Dex-LA micro-
sphere in cancer cells by means of cellular pinocytosis. It
could be seen that the microsphere prepared in this study
could be taken up by cells and accumulated in the cytoplasm.
Western blotting
In this experiment, Western Blotting was performed to
examine the expression of transcription factors IKK,
IκB, NF-κB, pIKK, and pIκB in B16F10 cancer cells.
There was no significant difference in the expression of
IKK, IκB, and NF-κB between the Control group and
FA-Dex-LA group after cancer cells were co-cultured
with drug for 24 hours, while the pIKK and pIκB
activities in IMD-0345 and IMD/FA-Dex-LA groups
were evidently dropped (Figure 5).
Anti-tumor effect
As shown in Figure 6A, tumors in the Control group
without any treatment kept growing, and the tumor
volume was about 390.6±43.1 mm3 on the 28th day. FA-
Dex-LA was injected at a dose of 40 mg/kg once every 3
days a total of five-times. The tumors in the FA-Dex-LA
group continued to grow, and the tumor volume was
about 300.0±45.3 mm3. Meanwhile, tumors in the
IMD0354 group were partially inhibited, with tumor
volumes of about 174.2±15.8 mm3. Compared with
other groups, tumors in the IMD0354/FA-Dex-LA group
0
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Figure 3 Cell cytotoxicity and proliferative analysis. (A) Biocompatibility of FA-Dex-LA microsphere on L929 cell; (B) IMD/FA-Dex-LA and simple IMD-0354 inhibited the
survival rate of B16F10 cell.
Abbreviations: Dex, dextran; FA, folate acid; LA, lauryl alcohol.
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Figure 4 FITC-FA-Dex-LA accumulation inB16F10 cell by cellular pinocytosis. A= the B16F10 cells, B= the microsphere carrier, and C= the uptake of the microspheres by
the cells.
Abbreviations: Dex, dextran; FA, folate acid; LA, lauryl alcohol.
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were obviously suppressed, with tumor volumes of about
53.2±10.3 mm3.
Moreover, the tumor tissue was removed and
weighed on the 28th day, as presented in Figure 6B. It
could be observed from the overall trend that the tumor
volume size was consistent with that on the 28th day in
Figure 6A.
Tumor tissue H&E staining after
treatment
At the end of treatment in the Control group, relatively dense
nuclei, relatively ordered cytoplasm, and good proliferation
capacity could still be observed (Figure 7A). Figure 7B
shows the results of FA-Dex-LA treatment. It could be
found that tumor cells had relatively complete cytoplasm,
although the peritoneal nuclei were slightly loose compared
with those in the Control group. Figure 7C displays the
results of IMD-0354 treatment. As could be found, the
nuclear density was markedly decreased, and many cytoplas-
mic defects began to appear. Figure 7D reveals the results of
IMD/FA-Dex-LA treatment. It could be discovered that the
nuclear density was apparently decreased, along with the
most serious cytoplasmic defect and numerous residual
voids, and only the residual cytoskeleton and part of the
cytoplasm wasleft.
Discussion
The dextran molecules have contained abundant active
groups (-OH); therefore, chemical reactions, such as
amide, can be employed to introduce other groups for
modification. This paper was carried out based on this
principle, and the active group on the dextran skeleton
grafted hydrophobic group cholesterol was utilized to obtain
the hydrophobic dextran derivatives. In addition, the final
reaction product, dextran derivative, was tested using the
KBr tablet and infrared spectrometer. The infrared spectra
are displayed in Figure 1. It could be seen from the figure
that the characteristic absorption peak of the functional
group could be detected at 1,697 cm−1 (C=O). Clearly, the
final product of dextran derivatives displayed the character-
istic absorption peak of LA at 1,643 cm−1. In the meantime,
the O-H absorption peak at 3,365 cm−1 was the
C-O-C Dextran characteristic absorption peak; meanwhile,
the lauryl alcohol-CH characteristic absorption peak in the
hydrophobic chain section of the structure could be detected
at ν=2,904 cm−1. All these features could also be detected in
FA-Dex-LA, indicating that the FA-Dex-LA had been suc-
cessfully prepared. According to the detection results of the
microsphere particle size, the average particle size was
increased after drug encapsulating, which might be because
the stereoscopic obstacles would be formed in the micro-
spheres when the hydrophobic drug molecules were
embedded in the microsphere core layer.13 Hence, the aver-
age particle size would be increased. When the drug release
test was conducted in vitro, the water molecules could
firstenter the microsphere, so the drugs could be released
due to the internal and external concentration difference.
Subsequently, the microsphere structure was loosened and
broken, as a result of the hydrolysis-induced breaking of the
ester linkage bonding on the FA-Dex-LA molecule chain
section. Hence, the drugs were released through the core
layer of microsphere. Du et al had assessed the release rate
of the dextran grafted stearate loaded drugs, and discovered
that nearly 50% of the drug amount could be accumulated
after 10 h, which was consistent with our results, but the
drug release mechanism in their study was hydrolytic
degradation.14 In addition, it is also suggested in research
that, when the amphoteric molecules in aqueous solution
Figure 5 Western blotting detected the expression of IKK,IκB,NF-κβ,pIKK and
pIκB in B16F10 cancer cells.
Abbreviations: Dex, Dextran; FA, Folate Acid; LA, Lauryl Alcohol.
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(microcell) can be formed by the self-assembly of water
texture features of materials, they will be able to spread into
the water molecule micell environment, and connect onto
the glucan ester chain key and biodegradable materials
through hydrolysis.15,16
In biocompatibility experiments, no statistically signif-
icant difference was observed compared with the control
group; so the result showed that FA-Dex-LA displayed no
cytotoxicity to fibroblast L929, which was a good biocom-
patibility carrier that could be utilized for subsequent
experiments to confirm the feasibility. It could be found
in cell proliferation experiments that the inhibition rates in
the two groups ofcells showed no statistically significant
difference at a drug concentration of <0.25 µg/mL.
However, at a drug concentration of >0.25 µg/mL, the
inhibition rate in the carrier group on cancer cells was
evidently higher than that in the single drug group,
which might be due to the different mechanisms of drugs
entering into cells. According to a literature report, cell
membranes are selectively permeable, which can diffuse
material or drug with the molecular weight of <1 kDa into
cells.17 Therefore, the simple IMD-0354 drug could enter
cells by means of diffusion. Conversely, the IMD/FA-Dex-
LA microsphere would enter cells through phagocytosis,
which would cause drug accumulation in cells, thus
achieving the drug inhibiting effect. To sum up, it is
confirmed in this experiment that drug effect was not
affected by the loading of microspheres, and an identical
drug effect could be achieved at a lower dose.
Noteworthily, the FA-Dex-LA microsphere surface
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prepared in this study had possessed an electrically neutral
hydrophilic shell Dextran, so it could relatively reduce the
barrier of cell pinocytosis resulting from the material sur-
face charge; besides, it had excellent solubility in aqueous
solution. Results of cellular pinocytosis also demonstrated
the feasibility of cancer cell phagocytic material.
Moreover, Western blotting suggested that both IMD-
0345 and IMD/FA-Dex-LA could evidently inhibit the
IKK pathway, while the expression of NF-κB and cyto-
plasmic NF-κB in cells was not changed, and NF-κB
expression in nuclei was markedly down-regulated, indi-
cating that the NF-κB nuclei were reduced after blocking
the IKK pathway, leading to the inhibition of melanoma
cell division and proliferation.
Further, we could more clearly verify whether the
vector could inhibit tumor growth after being loaded
with IMD0354 through subcutaneous tumor formation in
nude mice. On the 28th day after tumor implantation, the
tumor volume in nude mice treated with IMD/FA-Dex-LA
was the lowest. Apparently, the tumor growth rate in this
group was lower than those in other groups. Also, the
tumor weight in this group was lower than those in other
groups. In addition, it could be observed in HE staining
experiment that more severe tumor tissue damage could be
detected after IMD/FA-Dex-LA treatment. Hence, it can
be concluded that IMD/FA-Dex-LA can powerfully inhibit
the growth of the subcutaneously implanted tumors from
melanoma B16F10 cells.
Conclusions
Results in this study show that the IMD/FA-Dex-LA nano-
particles can reduce the toxicity of IMD0354 in the mean-
time of obviously improving the antitumor effect.
Therefore, FA-Dex-LA can serve as a safe and effective
carrier with great potential for application.
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